Author Archives: Isaura Santos

OU Researcher Is Advancing New Therapy For Alzheimer’s Disease

A scientist from the University of Oklahoma is developing a new therapy to address Alzheimer’s disease using “biopharmaceutical proteases” to destroy the toxic plaque that piles up in the brain of Alzheimer’s patients. This approach will have significantly lower costs in the treatment of the disease while at the same time it has the potential to…

Promising, New Alzheimer’s Drug To Enter Clinical Trials

A new drug developed at Lancaster University in the United Kingdom that might help to prevent early stages of Alzheimer’s disease and is about to enter clinical trials. The number of individuals affected by dementia is constantly increasing. According to estimates, there are 850,000 cases in the United Kingdom currently, with estimates that the number…

Aphios Granted Patent For Treatment Of Alzheimer’s Disease

Aphios Corporation recently announced that United States Patent 9,034,347 has been granted to the company’s lead compound to treat neurodegenerative diseases like Alzheimer’s disease, Parkinson’s disease, Hutchinson Disease and Down’s syndrome. Alzheimer’s disease, Parkinson’s disease, Hutchinson’s Disease, Kuru Creutzfeldt-Jakob disease, further spongiform encephalopathies and all neurodegenerative diseases in general remain enormous health problems with numerous…

Alzheimer’s Association Launches New Open-Access Journal

The existence of specific and reliable biomarkers for Alzheimer’s disease are crucial to identifying individuals to enroll in clinical trials so that drugs can be tested and diseases can be detected as soon as possible. Facilitating clinical trial enrollment allows studies that are researching and developing therapies that stop or slow Alzheimer’s disease progression…

NuevaCare Introduces MnemeTherapy® For Patients With Alzheimer’s

NuevaCare recently announced that it will be presenting MnemeTherapy®, its service to address Alzheimer’s disease, at two upcoming seminars. The first will be held on Wednesday, May 6 at the PSA Annual Regional Stroke Conference at The Magnolia of Millbrae; the second will take place on Wednesday, May 13 at the Dementia…

Cerespir Incorporated Appoints Sophie Egholm As The New Chief Operating Officer

CereSpir™ Incorporated, a biotechnology company firm advancing CSP-1103, which is a first-in-class modulator of the innate immune system of the brain to address treatment for Alzheimer’s disease, recently announced that Sophie Egholm has been appointed as Chief Operating Officer of the company. Egholm is a pharmacologist and medicinal chemist who has spent her…